SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its recent momentum and growing number of watchers, with many highlighting upcoming utilities. Community members are expressing bullish sentiment, anticipating further gains and airdrops for NFT holders. The conversation also reflects excitement around staking and the project's overall development.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as community members highlight its recent selection by the U.S. Department of Commerce to verify and distribute economic data onchain, marking a significant step for decentralized infrastructure. Discussions revolve around the potential impact of this government partnership and the long-term prospects of Pyth as a leading oracle in the crypto space. Some investors are comparing it to Chainlink and other real-world asset tokens.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to heightened attention surrounding the company's new commercial, with community members sharing their excitement after spotting it during NFL games and on YouTube. Despite positive reactions to the advertisement, some investors remain concerned about the stock's performance following the recent reverse split and broader challenges within the EV sector. Discussions also encompass perspectives on the company's long-term viability and potential for a short squeeze.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu ($SHI.X) is trending as community members highlight bullish chart patterns and anticipate a breakout, with some mentioning its connection to the Shiba Inu ecosystem. Discussions center around accumulation, strong support, and potential for significant upward movement. Some users are comparing it to other meme coins and highlighting its potential for charity burns.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to its inclusion in the S&P 500, sparking enthusiastic discussions around the potential for increased visibility and ETF buying.  While some community members are optimistic about continued momentum, others caution that the stock may be overvalued and due for a correction.  The inclusion highlights AppLovin's growth in the ad tech space, but also invites debate about long-term performance following index additions.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Traders are actively discussing GYRO due to its low float and potential for a significant price surge, with some highlighting a key breakout level that could trigger further momentum. Community members are also pointing to the company's underlying assets and liquidation strategy, suggesting the stock is undervalued. The stock is gaining increased attention, with many hoping to capitalize on a potential parabolic run.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending downwards after reports surfaced linking Tylenol use during pregnancy to autism, sparking concerns about potential liabilities and revenue impact. The community is debating the validity of these claims and the potential for a buying opportunity amidst the uncertainty, while some traders are taking a cautious stance due to headline risk and recent revenue misses.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to news of a closed $100M private placement and the launch of an Injective (INJ) digital asset treasury strategy, making it the first public company to hold INJ tokens. The community is actively discussing potential short squeezes and high volatility, while others caution about dilution. With a small float and high borrow costs, the stock has seen significant price swings, leading to both bullish and bearish sentiments.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure ($QURE) is trending amid discussions about its Fabry disease data and potential for its Huntington's disease treatment, AMT-130, driven by regulatory updates and analyst ratings. The community is focused on the company's CEO, data releases, and potential for accelerated approval. Some traders express concern about the stock's history and potential for dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vera Therapeutics stock sinks following competitor’s successful trial

Investing.com -- Shares of  Vera Therapeutics  (NASDAQ:VERA) tumbled by 33% in premarket trading today after a Japanese competitor, Otsuka, reported positive results from a Phase 3 trial of a competing kidney disease therapy. Otsuka’s announcement indicated that its drug, sibeprenlimab, achieved a 51.2% reduction in proteinuria in the treatment of immunoglobulin A nephropathy (IgAN), surpassing the results from Vera’s own candidate, atacicept.

Shares of Vera Therapeutics, Inc. (VERA) were in the spotlight on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-refinancing-existing-oxford-debt">announced</a> that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner, Oxford Finance LLC.The new credit facility will replace Vera’s existing $50 million credit facility. The initial funding of the new credit facility will be in a principal amount of $75 million and is expected to occur on June 4, 2025, the company said.The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.Vera Therapeutics is looking to submit a Biologics License Application to the U.S. Food and Drug Administration in the fourth quarter of this year for Atacicept. The company is looking forward to the potential commercialization of the investigational drug for the treatment of immunoglobulin A nephropathy (IgAN) in adults.IgA nephropathy, also known as Berger's disease, is a kidney disease where antibodies build up in the kidneys, causing inflammation and damage.Vera on Monday said that Atacicept achieved a 46% reduction from baseline in protein levels in the urine of 431 adults with IgA nephropathy being evaluated in a late-stage trial.VERA stock closed 67% higher on Monday on the news.On Stocktwits, retail sentiment around VERA stayed unmoved within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_03_at_8_05_39_AM_png_bf7adee158.webp" alt="VERA's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 3, 2025 | Source: Stocktwits" width="624" height="68"><figcaption>VERA's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 3, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user praised the company’s decisions.<stembedurl>https://stocktwits.com/US_Bull/message/616604119</stembedurl>Another expects the stock will hit $40 soon.<stembedurl>https://stocktwits.com/tomf95/message/616602882</stembedurl><a href="https://stocktwits.com/symbol/VERA">VERA stock</a> is down by 25% this year and by about 21% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/weride-partners-with-renault-for-autonomous-shuttle-service-at-the-french-open/chkr56IRbvO">WeRide Partners With Renault To Provide Autonomous Shuttle At The French Open, But Retail’s Not Excited</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40

The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.

Equity

The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.


Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options

Investors eyeing a purchase of Vera Therapeutics Inc (VERA) shares, but cautious about paying the going market price of 38.14/share, might benefit from considering selling puts among the...

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA Research Report), Tyra Bioscience (TYRA...

Vera Therapeutics reports FY23 EPS ($2.25) vs ($3.35) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and...

Vera Therapeutics (VERA, $44.19) Aroon Indicator entered an Uptrend on March 12, 2024.

Over the last three days, A.I.dvisor has detected that VERA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Vera Therapeutics (VERA, $43.15) Aroon Indicator entered an Uptrend on March 11, 2024.

Vera Therapeutics (VERA, $44.3) Aroon Indicator entered an Uptrend on March 08, 2024.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.15	--	--	N/A
Q2 '25	-$0.82	-$1.20	-46.06%	MISSED
Q1 '25	-$0.74	-$0.81	-9.27%	MISSED
Q4 '24	-$0.81	-$0.72	11.35%	BEAT
Q3 '24	-$0.64	-$0.85	-33.33%	MISSED

VERA
Vera Therapeutics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest VERA News

VERA Vera Therapeutics Inc - Ordinary Shares - Class A